Key Insights
- Using the 2 Stage Free Cash Flow to Equity, Tecan Group fair value estimate is CHF231
- With CHF198 share price, Tecan Group appears to be trading close to its estimated fair value
- The CHF285 analyst price target for TECN is 24% more than our estimate of fair value
How far off is Tecan Group AG (VTX:TECN) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to their present value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. Don't get put off by the jargon, the math behind it is actually quite straightforward.
We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.
See our latest analysis for Tecan Group
The Model
We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value:
10-year free cash flow (FCF) estimate
2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
Levered FCF (CHF, Millions) | CHF141.3m | CHF132.0m | CHF126.3m | CHF122.7m | CHF120.3m | CHF118.8m | CHF117.8m | CHF117.3m | CHF117.0m | CHF116.9m |
Growth Rate Estimate Source | Analyst x4 | Analyst x4 | Est @ -4.28% | Est @ -2.90% | Est @ -1.94% | Est @ -1.26% | Est @ -0.79% | Est @ -0.46% | Est @ -0.23% | Est @ -0.07% |
Present Value (CHF, Millions) Discounted @ 4.2% | CHF136 | CHF121 | CHF112 | CHF104 | CHF97.7 | CHF92.5 | CHF88.1 | CHF84.1 | CHF80.5 | CHF77.1 |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = CHF992m
After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 0.3%. We discount the terminal cash flows to today's value at a cost of equity of 4.2%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = CHF117m× (1 + 0.3%) ÷ (4.2%– 0.3%) = CHF3.0b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= CHF3.0b÷ ( 1 + 4.2%)10= CHF2.0b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is CHF3.0b. The last step is to then divide the equity value by the number of shares outstanding. Relative to the current share price of CHF198, the company appears about fair value at a 14% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.
Important Assumptions
We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Tecan Group as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 4.2%, which is based on a levered beta of 0.956. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Tecan Group
- Debt is not viewed as a risk.
- Dividends are covered by earnings and cash flows.
- Earnings declined over the past year.
- Dividend is low compared to the top 25% of dividend payers in the Life Sciences market.
- Annual earnings are forecast to grow faster than the Swiss market.
- Current share price is below our estimate of fair value.
- Revenue is forecast to grow slower than 20% per year.
Next Steps:
Although the valuation of a company is important, it ideally won't be the sole piece of analysis you scrutinize for a company. It's not possible to obtain a foolproof valuation with a DCF model. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. For Tecan Group, there are three important items you should assess:
- Risks: Be aware that Tecan Group is showing 1 warning sign in our investment analysis , you should know about...
- Future Earnings: How does TECN's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. Simply Wall St updates its DCF calculation for every Swiss stock every day, so if you want to find the intrinsic value of any other stock just search here.
Valuation is complex, but we're here to simplify it.
Discover if Tecan Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SWX:TECN
Tecan Group
Provides laboratory instruments and solutions for pharmaceutical, biotechnology and in-vitro diagnostic companies, university research departments, and diagnostic and other laboratories.
Excellent balance sheet average dividend payer.